Allogene Therapeutics Inc (ALLO)
EBITDA Margin
-3287.20%
TTM · Period ending:
ALLO EBITDA Margin
Latest reported-3287.20%period ending
Latest reported-3287.20%period ending
ALLO TTM EBITDA Margin (-569.25% → -3287.20%)
TTM ebitda margin
High-resolution chart · PNG
ALLO ebitda margin history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Margin |
|---|---|
| -3,287.1983% | |
| -1,106,031.8182% | |
| 1,161,804.5455% | |
| -1,200,913.6364% | |
| -997,390% | |
| -266,565.2893% | |
| -231,835.8108% | |
| -159,735.8491% | |
| -131,002.8807% | |
| -120,317.4089% | |
| -118,927.9352% | |
| -142,249.7561% | |
| -641.0585% | |
| -612.9533% | |
| -588.6608% | |
| -569.2502% |